by Raul Lopez | Sep 23, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Psychedelic culture has a talent for turning an interesting observation into a religion by Tuesday. Psychedelic-assisted approaches are being studied for alcohol, tobacco and other substance-use disorders, with some encouraging results. Addiction is still a chronic, relapsing condition shaped by biology, trauma, environment and access to care—not a boss battle defeated by one transcendent afternoon.
The comparison group problem
Psilocybin studies in alcohol and tobacco use disorders have produced promising signals, but sample sizes and treatment models vary. The distinction is not academic housekeeping. It changes what a reader should actually believe, worry about or do with the information.
How strong is the signal?
A 2025 systematic review described the evidence as promising but still uncertain across substance-use disorders. Culture supplies meaning faster than science supplies certainty. That is not a flaw; it is simply a reason to label the two correctly.
Where this leaves the field
Established medications for opioid and alcohol use disorders reduce harm and mortality; experimental psychedelic treatments should not be framed as ideological replacements. A sober reading does not mean a boring reading. It means the weirdness has to earn its adjectives.
What follow-up tells us
Integration, follow-up and social support matter because reducing craving for a week is not the same thing as rebuilding a life. The boring caveat is often the important bit: who was studied, under what conditions, compared with what, and for how long?
The result is not a verdict so much as a useful boundary line. On one side are findings and documented history; on the other are interpretations that may be valuable without being settled facts.
A less mystical conclusion
Psychedelic subjects do not need inflated claims to be strange, culturally important or worth studying. The evidence is allowed to be incomplete. The art, history and human behavior around it are interesting enough without borrowing certainty from the future.
For the other side of the subject, see How to Talk to Your Doctor About Psychedelic Therapy Without Making It Weird.
The studio version of the idea
Consider this the hard border between information and merchandise. On the other side: artwork inspired by the topic, with no therapeutic claims attached. Browse Psychonaut art & clothing, the psychedelic T-shirts collection, or see Psychedelic Research Volunteer T-shirt.
Sources and further reading
by Raul Lopez | Sep 22, 2024 | blog
This topic attracts two kinds of writing: breathless evangelism and joyless debunking. Both are lazy. Integration circles can give people a place to talk through confusing experiences without turning every revelation into a diagnosis. They can also become echo chambers where the loudest mystical interpretation wins. Community helps; critical thinking still needs a chair.
Why the symbol refuses to die
Peer support can reduce isolation and help people translate intense experiences into ordinary language. The boring caveat is often the important bit: who was studied, under what conditions, compared with what, and for how long?
What history does to a good myth
A circle is not automatically therapy, and facilitators should be clear about scope, confidentiality and crisis procedures. If that sounds less cinematic, good. Cinema has editors. Biology, law and human psychology are rarely so considerate.
Why the idea stuck
Groups can unintentionally reinforce grandiosity, paranoia or certainty if every interpretation is validated as literal truth. One study can move a question forward without settling it. Psychedelic headlines occasionally struggle with this modest concept.
The cultural residue
Good integration makes room for meaning and skepticism at the same time—a surprisingly rare social skill. The real signal is easier to see once “promising,” “proven” and “possible” stop being treated as synonyms.
The larger pattern is less tidy than the usual headline but more informative. Different mechanisms, settings and people produce different outcomes, and a serious account has to make room for that variability.
Where that leaves us
There is enough here to justify attention and not enough to justify evangelism. That middle ground is less marketable, admittedly, but it is also where most serious understanding begins.
From here, the obvious rabbit hole is Psychedelics and Creativity: Inspiration, Disruption and the Myth of the Automatic Genius.
The studio detour
The theory is one thing. The visual residue it leaves in psychedelic art is another, and frankly much easier to hang on a wall. Browse Psychonaut art & clothing, the psychedelic journals and notebooks collection, or see The Psychonaut poster.
by Raul Lopez | Sep 19, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Ayahuasca ceremonies range from Indigenous and religious traditions to expensive international retreats with branding decks. Treating all of them as the same thing is culturally lazy and a safety problem.
Start with the boring facts
Ayahuasca commonly combines DMT-containing plants with beta-carboline MAO inhibitors, which creates meaningful medication and interaction risks. That is a narrower claim than the mythology usually offers, but narrower claims have the useful habit of being checkable.
Why context can change the danger
Screening quality, facilitator training, emergency planning, consent practices and group size can vary enormously between settings. A useful explanation should survive contact with the awkward details, including the details that refuse to fit the preferred narrative.
Where uncertainty increases risk
Vomiting may be culturally interpreted as cleansing, but severe dehydration, dangerous interactions or medical symptoms should not be spiritualized away. Sometimes the most useful answer is “we do not know yet,” provided we are precise about what is already known around the edges.
The part worth taking seriously
Indigenous knowledge deserves more than decorative borrowing; lineage, community context and reciprocity matter when outsiders commercialize ceremonial practices. That distinction is easy to lose once a striking story starts circulating faster than the evidence attached to it.
Put together, those pieces make a better map than the old yes-or-no framing. The subject remains interesting precisely because some parts are established, some are plausible and some are still genuinely unresolved.
So what survives the trip?
The useful version of this subject is the one that still makes sense after the adjectives come off. Keep what is documented, label what is interpretation, and leave the genuinely open questions open. They are usually the most interesting part anyway.
Keep going with Indigenous Wisdom and Modern Psychedelics: Borrow Less, Learn More.
Where the science ends and the art starts
PsychonautDream is an art project, not a clinic, pharmacy or legal service. If you came for the visual culture rather than a treatment protocol, the related collections are a safer place to wander. Browse Ayahuasca-inspired art & apparel, the psychedelic journals and notebooks collection, or see Mother Ayahuasca journal.
Sources and further reading
by Raul Lopez | Sep 15, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
Here is the useful version, without the incense-cloud certainty: PTSD is one of the most visible targets in psychedelic medicine, especially because of MDMA-assisted therapy research and emerging psilocybin studies. The evidence is promising, regulatory status remains unsettled, and “psychedelic therapy” is not one interchangeable treatment.
What follow-up tells us
MDMA-assisted therapy produced large symptom reductions in Phase 3 trials, but the FDA rejected the original application in 2024 and a resubmission was reported in August 2026. Culture supplies meaning faster than science supplies certainty. That is not a flaw; it is simply a reason to label the two correctly.
Why setting is part of the intervention
Psilocybin research in PTSD is much earlier than the depression evidence base. A sober reading does not mean a boring reading. It means the weirdness has to earn its adjectives.
Risk, screening and context
Trauma treatment requires attention to dissociation, consent, therapist boundaries and post-session support. The boring caveat is often the important bit: who was studied, under what conditions, compared with what, and for how long?
Who gets screened out matters
A treatment can be both promising and not yet approved; regulatory friction is not proof of conspiracy or proof of inefficacy. If that sounds less cinematic, good. Cinema has editors. Biology, law and human psychology are rarely so considerate.
None of this requires treating psychedelic experience as trivial. It requires the opposite: taking it seriously enough not to decorate weak claims until they look strong.
The bit worth remembering
The strongest takeaway is not a slogan. It is a boundary: what we know, what we suspect, what people report and what culture has layered on top. Once those are separated, the subject gets clearer without becoming dull.
The cluster continues in Psychedelics and Older Adults: What We Know, What We Definitely Don’t.
Where the science ends and the art starts
PsychonautDream is an art project, not a clinic, pharmacy or legal service. If you came for the visual culture rather than a treatment protocol, the related collections are a safer place to wander. Browse Psychonaut art & clothing, the psychedelic T-shirts collection, or see Psychedelic Research Volunteer T-shirt.
Sources and further reading
by Raul Lopez | Sep 13, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
This topic attracts two kinds of writing: breathless evangelism and joyless debunking. Both are lazy. Most psychedelic effects end within hours, but people can report lasting changes in mood, beliefs, behavior and perception. “Lasting” can mean beneficial, neutral or unwanted, and the internet has a bad habit of discussing only the first category.
Who gets screened out matters
Clinical studies sometimes find symptom improvement weeks or months after one or a few supported sessions, but those results come from screened participants. There are real questions here. They become easier to see once the promotional fog and psychedelic folklore are moved out of the way.
The less glamorous safety questions
Persistent perceptual changes such as HPPD are uncommon but real and can be distressing. The strongest version of the idea is usually the one that needs the fewest miracles to stay standing.
What the studies do not prove
Mania, psychosis, anxiety or destabilization appear rare in trials partly because higher-risk participants are usually excluded. There is a difference between respecting an experience and accepting every explanation attached to it. We can manage both.
Promising is not the same as approved
The long-term question is not just “did the trip end?” but whether sleep, functioning, mood, perception and relationships returned to a stable baseline. Anecdotes can point toward a question, but they cannot do the statistical heavy lifting simply because the anecdote is spectacular.
What survives scrutiny is still worth discussing. What does not survive can be retired without mourning; there will be no shortage of strange material left over.
After the smoke clears
Once the mythology, headlines and salesmanship are stripped away, there is usually still something genuinely interesting left. That is the part worth writing about—and the part worth returning to when new evidence appears.
A related piece worth opening next is Psychedelics and Addiction Treatment: Promise Without the Miracle-Cure Nonsense.
The cultural afterimage
A clinical or legal question should end with evidence, not a sales pitch. For readers interested in how the subject appears in psychedelic visual culture, these are the relevant studio links. Browse Psychonaut art & clothing, the psychedelic journals and notebooks collection, or see The Psychonaut poster.
Sources and further reading
by Raul Lopez | Sep 12, 2024 | blog
Updated September 2026. This article is educational and is not medical or legal advice.
“Micro” describes an intention to use a low amount; it does not mean risk disappears. Research on repeated low-dose psychedelic use is still limited, products are not standardized in unregulated settings, and interactions or psychiatric vulnerability do not care about branding.
What makes the situation riskier
Reported microdosing benefits are difficult to separate from expectancy effects in blinded research. The temptation to universalize is understandable. Human beings encounter one enormous experience and immediately start writing laws for the cosmos.
When the story stops being recreational
Repeated exposure raises unanswered questions about long-term patterns, individual sensitivity and interactions. The useful boundary is not between wonder and skepticism; it is between a claim we can inspect and a story we merely enjoy repeating.
What the body does not care about
People with bipolar-spectrum or psychotic disorders, significant cardiovascular disease or complex medication regimens may face different risks than healthy volunteers. There is no need to sand the mystery out of the subject. We can keep the mystery and stop pretending it already came with footnotes.
Start with the boring facts
Harm reduction starts with not pretending a popular practice has already passed the evidence tests we would demand of a medicine. The practical question is what this changes for the reader, not whether it can be made to sound profound in a caption.
The important thing is to keep the layers separate: pharmacology, personal report, cultural interpretation and commercial mythology. They interact constantly, but they are not interchangeable forms of evidence.
No cosmic receipt required
A subject can matter without proving a universal theory of consciousness, curing modern life or revealing what the universe “really” is. Sometimes the honest conclusion is narrower—and much more useful.
Another piece in the same orbit is Psilocybin Therapy for Depression: Where the Evidence Stands in 2026.
The studio version of the idea
Consider this the hard border between information and merchandise. On the other side: artwork inspired by the topic, with no therapeutic claims attached. Browse Magic mushroom art & clothing, the psychedelic T-shirts collection, or see Microdosing Explained T-shirt.
Sources and further reading
